Venetoclax
Hematopoietic And Lymphoid Cell Neoplasm
Explore 115 assets in Hematopoietic And Lymphoid Cell Neoplasm →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
University of Alabama at Birmingham
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07044544CT.gov Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | — | Recruiting | — | — | — |
NCT05529069CT.gov Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | — | Recruiting | — | — | — |
NCT04874194CT.gov Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | — | Terminated | — | — | — |
NCT04752163CT.gov DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT04809181CT.gov Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hematopoietic And Lymphoid Cell Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Venetoclax (this asset) | University of Alabama at Birmingham | P2 | B · 59 |
| Pegloticase | M.D. Anderson Cancer Center | P4 | BB |
| Nivestim | St. Jude Children's Research Hospital | P2 | BB |
| Rasburicase | M.D. Anderson Cancer Center | P4 | BB |
| Cyclosporin A | Children's Oncology Group | P3 | BB |
| Hydromorphon | M.D. Anderson Cancer Center | P4 | BB |
| Prednisone | M.D. Anderson Cancer Center | P2 | BB |
| Fludarabine | National Cancer Institute (NCI) | P3 | BB |
| Tacrolimus | Fred Hutchinson Cancer Center | P2 | BB |
+42 more in the Hematopoietic And Lymphoid Cell Neoplasm cohort
Other indications for Venetoclax
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P4 | BB · 70 |
| Acute Myeloid Leukemia | — | P4 | BB · 69 |
| Chronic Myelomonocytic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Venetoclax in Hematopoietic And Lymphoid Cell Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/venetoclax-hematopoietic-and-lymphoid-cell-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →